Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation

Stem Cells and Development

Volumn 22, Issue 9, 2013, Pages 1370-1386

  Akimoto, Keiko ^a   Kimura, Kenichi ^a   Nagano, Masumi ^a   Takano, Shingo ^a   To'A Salazar, Georgina ^a   Yamashita, Toshiharu ^a   Ohneda, Osamu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CHEMOKINE RECEPTOR CXCR4; DEATH RECEPTOR 4; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; MESSENGER RNA; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ADIPOSE TISSUE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UMBILICAL CORD BLOOD;

ADIPOSE TISSUE; ANGIOPOIETIN-1; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL PROLIFERATION; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FETAL BLOOD; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTORS, CXCR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876943017     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0486     Document Type: Article

References (66)

1. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig & DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
2. Kern S, H Eichler, J Stoeve, H Kluter & K Bieback. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-1301.
3. Zuk PA, M Zhu, H Mizuno, J Huang, JW Futrell, AJ Katz, P Benhaim, HP Lorenz & MH Hedrick. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228.
4. Asakura A, M Komaki & M Rudnicki. (2001). Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic & adipogenic differentiation. Differentiation 68:245-253.
5. De Bari C, F Dell'Accio, P Tylzanowski & FP Luyten. (2001). Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 44:1928-1942.
6. Gronthos S, M Mankani, J Brahim, PG Robey & S Shi. (2000). Postnatal human dental pulp stem cells (DPSCs) in vitro & in vivo. Proc Natl Acad Sci U S A 97:13625-13630.
7. Nagano M, K Kimura, T Yamashita, K Ohneda, D Nozawa, H Hamada, H Yoshikawa, N Ochiai & O Ohneda. (2010). Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. Stem Cells Dev 19:1195-1210.
8. Bieback K, S Kern, H Kluter & H Eichler. (2004). Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22:625-634.
9. Parolini O, F Alviano, GP Bagnara, G Bilic, HJ Buhring, M Evangelista, S Hennerbichler, B Liu, M Magatti, et al. (2008). Concise review: isolation & characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 26:300-311.
10. Tran TC, K Kimura, M Nagano, T Yamashita, K Ohneda, H Sugimori, F Sato, Y Sakakibara, H Hamada, et al. (2011). Identification of human placenta-derived mesenchymal stem cells involved in re-endothelialization. J Cell Physiol 226:224-235.
11. De Coppi P, G Bartsch, Jr., MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, et al. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100-106.
12. Ciavarella S, F Dammacco, M De Matteo, G Loverro & F Silvestris. (2009). Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. Stem Cells Dev 18:1211-1220.
13. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop & E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
14. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608.
15. Studeny M, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, BN Bekele, RE Champlin & M Andreeff. (2004). Mesenchymal stem cells: potential precursors for tumor stroma & targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603.
16. Ciavarella S, M Dominici, F Dammacco & F Silvestris. (2011). Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev 20:1-10.
17. Nakamizo A, F Marini, T Amano, A Khan, M Studeny, J Gumin, J Chen, S Hentschel, G Vecil, et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318.
18. Kang SG, SS Jeun, JY Lim, SM Kim, YS Yang, WI Oh, PW Huh & CK Park. (2008). Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells. Childs Nerv Syst 24:293-302.
19. Hong X, C Miller, S Savant-Bhonsale & SN Kalkanis. (2009). Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64:1139-1147.
20. Hamada H, M Kobune, K Nakamura, Y Kawano, K Kato, O Honmou, K Houkin, T Matsunaga & Y Niitsu. (2005). Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 96:149-156.
21. Kim SM, JY Lim, SI Park, CH Jeong, JH Oh,MJeong,WOh, SH Park, YC Sung & SS Jeun. (2008). Gene therapy using TRAILsecreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68:9614-9623.
22. Menon LG, K Kelly, HW Yang, SK Kim, PM Black & RS Carroll. (2009). Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27:2320-2330.
23. Stupp R, WP Mason, MJ van den Bent, M Weller, B Fisher, MJ Taphoorn, K Belanger, AA Brandes, C Marosi, et al.; European Organisation for Research & Treatment of Cancer Brain Tumor & Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant & adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
24. De Vleeschouwer S, F Van Calenbergh, P Demaerel, P Flamen, S Rutkowski, E Kaempgen, JE Wolff, C Plets, R Sciot and SW Van Gool. (2004). Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100:492-497.
25. Zhao D, J Najbauer, E Garcia, MZ Metz, M Gutova, CA Glackin, SU Kim & KS Aboody. (2008). Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res 6:1819-1829.
26. Ahmed AU, MA Tyler, B Thaci, NG Alexiades, Y Han, IV Ulasov & MS Lesniak. (2011). A comparative study of neural & mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharmacol 8:1559-1572.
27. Zhu W, W Xu, R Jiang, H Qian, M Chen, J Hu, W Cao, C Han & Y Chen. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80:267-274.
28. Yu JM, ES Jun, YC Bae & JS Jung. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 17:463-473.
29. Valter MM, OD Wiestler & T Pietsche. (1999). Differential control of VEGF synthesis & secretion in human glioma cells by IL-1 & EGF. Int J Dev Neurosci 17:565-577.
30. Hao C, IF Parney, WH Roa, J Turner, KC Petruk & DA Ramsay. (2002). Cytokine & cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 103:171-178.
31. Louis DN, H Ohgaki, OD Wiestler, WK Cavenee, PC Burger, A Jouvet, BW Scheithauer & P Kleihues. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
32. Nagano M, T Yamashita, H Hamada, K Ohneda, K Kimura, T Nakagawa, M Shibuya, H Yoshikawa & O Ohneda. (2007). Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood 110:151-160.
33. Folkerth RD. (2004). Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res 117:79-95.
34. Hattermann K, J Held-Feindt, R Lucius, SS Muerkoster, ME Penfold, TJ Schall & R Mentlein. (2010). The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 70:3299-3308.
35. Yang B, X Wu, Y Mao, W Bao, L Gao, P Zhou, R Xie, L Zhou and J Zhu. (2009). Dual-targeted antitumor effects against brainstem glioma by intravenous delivery. Neurosurgery 65:610-624.
36. Abbott JD, Y Huang, D Liu, R Hickey, DS Krause & FJ Giordano. (2004). Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110:3300-3305.
37. Mohle R, F Bautz, S Rafii, MA Moore, W Brugger & L Kanz. (1998). The chemokine receptor CXCR-4 is expressed on CD34 + hematopoietic progenitors & leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91:4523-4530.
38. Son BR, LA Marquez-Curtis, M Kucia, M Wysoczynski, AR Turner, J Ratajczak,MZ Ratajczak & A Janowska-Wieczorek. (2006). Migration of bone marrow & cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 & hepatocyte growth factor-c-met axes & involves matrix metalloproteinases. Stem Cells 24:1254-1264.
39. Bajetto A, F Barbieri, A Dorcaratto, S Barbero, A Daga, C Porcile, JL Ravetti, G Zona, R Spaziante, et al. (2006). Expression of CXC chemokine receptors 1-5 & their ligands in human glioma tissues: role of CXCR4 & SDF1 in glioma cell proliferation & migration. Neurochem Int 49:423-432.
40. Dewan MZ, S Ahmed, Y Iwasaki, K Ohba, M Toi & N Yamamoto. (2006). Stromal cell-derived factor-1 & CXCR4 receptor interaction in tumor growth & metastasis of breast cancer. Biomed Pharmacother 60:273-276.
41. Holland JD, M Kochetkova, C Akekawatchai, M Dottore, A Lopez & SR McColl. (2006). Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 66:4117-4124.
42. Hong X, F Jiang, SN Kalkanis, ZG Zhang, XP Zhang, AC DeCarvalho, M Katakowski, K Bobbitt, T Mikkelsen & M Chopp. (2006). SDF-1 & CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett 236:39-45.
43. Ma M, JY Ye, R Deng, CM Dee & GC Chan. (2011). Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 & SDF-1/CXCR7 signaling. Cancer Lett 312:1-10.
44. Park SA, CH Ryu, SM Kim, JY Lim, SI Park, CH Jeong, JA Jun, JH Oh, SH Park, W Oh & SS Jeun. (2011). CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int J Oncol 38:97-103.
45. Sun X, G Cheng, M Hao, J Zheng, X Zhou, J Zhang, RS Taichman, KJ Pienta & J Wang. (2010). CXCL12/CXCR4/CXCR7 chemokine axis & cancer progression. Cancer Metastasis Rev 29:709-722.
46. Rempel SA, S Dudas, S Ge & JA Gutierrez. (2000). Identification and localization of the cytokine SDF1 & its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6: 102-111.
47. Salmaggi A, M Gelati, B Pollo, C Marras, A Silvani, MR Balestrini, M Eoli, L Fariselli, G Broggi & A Boiardi. (2005). CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol 74:287-293.
48. Yamanaka R, R Tanaka, T Saitoh & S Okoshi. (1994). Cytokine gene expression on glioma cell lines & specimens. J Neurooncol 21:243-247.
49. Hermanson M, K Funa, M Hartman, L Claesson-Welsh, CH Heldin, B Westermark & M Nister. (1992). Platelet-derived growth factor & its receptors in human glioma tissue. Cancer Res 52:3213-3219.
50. Burns JM, BC Summers, Y Wang, A Melikian, R Berahovich, Z Miao, ME Penfold, MJ Sunshine, DR Littman, et al. (2006). A novel chemokine receptor for SDF-1 & I-TAC involved in cell survival, cell adhesion & tumor development. J Exp Med 203:2201-2213.
51. Miao Z, KE Luker, BC Summers, R Berahovich, MS Bhojani, A Rehemtulla, CG Kleer, JJ Essner, A Nasevicius, et al. (2007). CXCR7 (RDC1) promotes breast & lung tumor growth in vivo & is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 104:15735-15740.
52. Raggo C, R Ruhl, S McAllister, H Koon, BJ Dezube, K Fruh and AV Moses. (2005). Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcomaassociated herpesvirus. Cancer Res 65:5084-5095.
53. Balabanian K, B Lagane, S Infantino, KY Chow, J Harriague, B Moepps, F Arenzana-Seisdedos, M Thelen & F Bachelerie. (2005). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280:35760-35766.
54. Infantino S, B Moepps & M Thelen. (2006). Expression and regulation of the orphan receptor RDC1 & its putative ligand in human dendritic & B cells. J Immunol 176:2197-2207.
55. Jones SW, SM Brockbank, ML Mobbs, NJ Le Good, S Soma-Haddrick, AJ Heuze, CJ Langham, D Timms, P Newham and MR Needham. (2006). The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. Osteoarthritis Cartilage 14:597-608.
56. Okada H, T Nakajima, T Yoshimura, K Yasuda & H Kanzaki. (2003). Microarray analysis of genes controlled by progesterone in human endometrial stromal cells in vitro. Gynecol Endocrinol 17:271-280.
57. Wang J, Y Shiozawa, Y Wang, Y Jung, KJ Pienta, R Mehra, R Loberg & RS Taichman. (2008). The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283:4283-4294.
58. Salvucci O, L Yao, S Villalba, A Sajewicz, S Pittaluga & G Tosato. (2002). Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99:2703-2711.
59. Ping YF, XH Yao, JH Chen, H Liu, DL Chen, XD Zhou, JM Wang & XW Bian. (2007). The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells. J Neurooncol 84:21-29.
60. Zhou Y, PH Larsen, C Hao & VW Yong. (2002). CXCR4 is a major chemokine receptor on glioma cells & mediates their survival. J Biol Chem 277:49481-49487.
61. Aboody KS, J Najbauer & MK Danks. (2008). Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15:739-752.
62. Sasportas LS, R Kasmieh,HWakimoto, S Hingtgen, JA van de Water, G Mohapatra, JL Figueiredo, RL Martuza, R Weissleder and K Shah. (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 106:4822-4827.
63. Cavarretta IT, V Altanerova, M Matuskova, L Kucerova, Z Culig & C Altaner. (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 18:223-231.
64. Kucerova L, V Altanerova, M Matuskova, S Tyciakova and C Altaner. (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67:6304-6313.
65. Nakamura K, Y Ito, Y Kawano, K Kurozumi, M Kobune, H Tsuda, A Bizen, O Honmou, Y Niitsu & H Hamada. (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11:1155-1164.
66. Uchibori R, T Okada, T Ito, M Urabe, H Mizukami, A Kume and K Ozawa. (2009). Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11:373-381.